RBC Capital ups price target on Hikma
By Abigail Townsend
Date: Tuesday 20 May 2025
(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.
The broker said Hikma had recently provided mid-term guidance that "reflects growing optimism about the Rx and injectables businesses".
It continued: "This adds to the positive outlook for the branded unit, communicated in late 2024. Overall, Hikma anticipates three-year revenue growth of 6% to 8% per annual, and core operating profit growth of 7% to 9% per annum."
RBC has therefore increased its 2027 forecasts for earnings before interest and tax by 9%, and the price target by 3%, to 2,635p.
It concluded: "With 27% upside, we reiterate our 'outperform' recommendation."
As at 1330 BST, shares in Hikma were largely flat at 2,078p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN